The following archived links to
news, company press releases and other information sources
are provided as a service by the Angioplasty.Org, which
is not responsible for the content found on these external
sites.
If you wish a different date range,
select a news archive, or our special Drug-Eluting Stent
NewsCenter, from the following menu:
December 30, 2004 Private
Sector Tsunami Aid Grows
Pharmaceutical and medical device companies have pledged significant
funds to aid South Asia in the aftermath of the tragic tsunami that has
taken over 125,000 lives. Pfizer tops the list with a pledge of $35 million
($10 million in cash, the rest in medical supplies) equaling the entire
initial aid package promised by the Bush administration (note: U.S. government
aid was increased ten-fold to $350 million on Friday, December 31). Johnson & Johnson
and Abbott have each pledged $2 million (Abbott
recently upped their contribution to $4 million), with Merck
coming in at $250,000 and Boston Scientific at $100,000. You can donate
through any number of organizations -- go to the Washington Post article "How
You Can Help" for more information. (source: Matthew Goldstein, TheStreet.com)
December 17, 2004 Bush
Chief Speechwriter Has Coronary Procedure
George W. Bush's chief speechwriter, Michael Gerson, underwent successful
angioplasty and received two coronary stents to reopen partially blocked
vessels on Friday after suffering chest pains. (source: Reuters)
(Special Section)
Johnson & Johnson Agrees to Buy Guidant
December 16, 2004 J&J
sees no antitrust roadblocks to Guidant deal
Although a topic which has been discussed about the merging of
these two cardiology units, J&J seems to feel there won't be
any significant problems. (Note: see Editor's
blog for more about this issue.) (source: Reuters)
December 15, 2004 Johnson & Johnson
and Guidant Announce Definitive Agreement Valued
at $23.9 Billion Based on $76 per Share
They just celebrated their 10th anniversary yesterday -- and today
they are announcing they will become part of the healthcare giant
Johnson & Johnson. Their official press release states that
the "Transaction will bring together cardiovascular expertise
and technologies to benefit patients and physicians worldwide." (source: Guidant Corporation / Johnson & Johnson)
December 14, 2004 J&J-Guidant
Deal Could Aid Boston Scientific - Analysts
How could the teaming up of two major competitors help the third?
By slowing down the current Guidant pipeline, says Deutsche Bank
analyst Tao Levy -- short term. But long term is a bit different
story. (source: Susan Kelly, Reuters)
December 13, 2004 J&J:
Don't Stop Dealmaking Now
Patent expirations and a thin pipeline mean the giant needs more
than Guidant. (source: Amy Barrett & Michael Arndt, BusinessWeek
Online)
December 12, 2004 Sale
would be premium for execs: Top Guidant officials
stand to gain millions from transaction
What happens to the a company when it is bought by another? This
article details the various agreements in place that will be triggered
if the merger is voted on (executives from both J&J and Guidant
are scheduled to meet this Sunday evening to discuss and possibly
vote on the merger). (source: Jeff Swiatek, Indianapolis Star)
December 10, 2004 Guidant
deal seen insulating J&J from drug exposure
Another article about the implications of the merger, with a very
specific opinion from an interventional cardiologist, regarding
his current choices of drug-eluting stents: "Dr. Samin
Sharma, head of interventional cardiology at Mt. Sinai Medical
Center, said he and many other cardiologists are hoping J&J
will buy Guidant and coat the smaller company's highly maneuverable
bare metal Vision stent with sirolimus. "It would be a marriage
made in heaven -- the most flexible stent on the market coated
with the best drug, and that's why J&J and Guidant need each
other." (source: Ransdell Pierson, Reuters)
December 10, 2004 Johnson & Johnson
near Guidant deal
MarketWatch reports on a Wall Street Journal source that the two
companies have scheduled a Sunday Board meeting and that the merger
may be announced by Monday. Stay tuned. (source: CBS MarketWatch)
December 9, 2004 J&J,
Guidant Talks Undeterred by Overlap
Rumor swirls have included talk of anti-trust regulations forcing
J&J to sell off Guidant's stent business, but that is not the
plan, according to "sources familiar with the situation",
who also hint that the deal might be sealed as early as Monday. (source: Reuters)
December 9, 2004 Abbott
has an eye on stent firms' merger talk
More analysts discuss the effect the merger might have on the current
and future players in the stent market. (source: Bruce Japsen, Chicago Tribune)
December 8, 2004 J&J
Guided to Guidant?
The possible merger between device heavies is discussed from the
business side by Motley Fool (free registration required). There's
been much speculation about the meaning of such a merger (see articles
below) -- The Fool characterizes it as a "massive...broadside
aimed squarely at key competitors Boston Scientific and Medtronic." (Read
my comments in my blog, The
Voice in the Ear -- ed.) (source: Dave Marino-Nachison, The Motley Fool)
December 8, 2004 Guidant
Acquisition Would Benefit St. Jude
Adding to the instant analyses of a much-speculated-upon event,
Forbes reports that Credit Suisse First Boston thinks the merger
between J&J and Guidant might have positive effects for St.
Jude, and also "slight positives" for Boston Scientific
and Medtronic. (source: Forbes.com)
December 8, 2004 Johnson & Johnson
Decides It Needs Devices
An update on the possible J&J / Guidant merger and the impact
that it will have on the field of medical devices. (source: Barnaby J. Feder, New York Times)
December
7, 2004 Johnson & Johnson
Said to Be in Talks for Heart Device
Maker
Is J&J going to buy Guidant? Rumors swirl as Ron Dollens is
about to step down as CEO of Guidant at the end of this month with
no successor yet named. After all, Guidant is currently a marketing
partner, selling J&J's CYPHER™ drug-eluting stent. Such
a move would certainly change the playing field in the "Stent
Wars". A breaking story from the New Your Times (free
registration from NYT is required to read it.) (source: Andrew Ross Sorkin and Barnaby J. Feder, New
York Times)
November 16, 2004 The
Claim: Sex Can Set Off a Heart Attack
The "REALLY?" column discusses whether or not this is true.
For more information about heart disease, love and sex, read this
article from the Canadian Heart and Stroke Foundation. (source: Anahad O'Connor, New York Times)
November 13, 2004 Cheney,
Short of Breath, Heads to Hospital Cheney
Leaves Hospital
Vice President Dick Cheney, who had a stent and ICD implanted back in
2001 and has had a history of heart trouble, was being taken to a hospital
on Saturday for tests after experiencing some shortness of breath, which
a White House spokesman said might be attributable to a bad cold he has
had. The second article reports that Cheney "feels fine" and
no problems were found. (source: Deb Riechmann, Associated Press / CBS News)
November 7,
2004 Coronary
Stents Do Not Improve Long-Term Survival
A study, presented by Duke cardiologist David Kandzari, M.D. at this
year's American Heart Association meeting, shows that stenting has little
effect on survival rates of patients with CAD, However, stenting does
reduce the need for repeat procedures and does have a role in preventing
the pain associated with CAD (angina). There is also a suggestion that
some patients would be better served through bypass surgery. The study
was done before drug-eluting stents were available, but the author hypothesizes
that the results from drug-eluting stents will be similar. (source: Duke University Medical Center)
October 21, 2004 Guidant
Begins Enrollment in New Study of Carotid Stenting
The company is beginning enrollment in the CAPTURE (Carotid ACCULINK/ACCUNET
Post Approval Trial to Uncover Rare Events) post-approval study, required
by the F.D.A. Approximately 1,500 patients who receive the newly-approved
carotid stent will be studied for longer term outcomes. Currently the
Guidant ACCULINK carotid stent is the only such device approved in the
U.S. In this company release, Beverly Huss, president of Guidant Endovascular
Solutions, states, "For patients who are ineligible or at high risk
for traditional surgery, carotid stenting provides a minimally invasive
breakthrough therapy to reduce the risk of stroke. This additional data
on carotid stenting performed by a variety of physicians from across
the nation will further advance our knowledge of this important new therapy." (source: Guidant Corporation)
October 13, 2004 Boston
Scientific Announces FDA Clearance For New IQ™ Guide
Wire
Company press release in which Dr. Stephen P. Wiet of Advocate Christ
Medical Center in Oak Lawn, Illinois states, "Often, devices undergo
changes that show promise on paper, but don't pan out in clinical practice...The
IQ Guide Wire blends characteristics of several individual guide wires
into a versatile workhorse version that delivers outstanding performance
in clinical application. The result is a high-tech performance boost
to our interventional practice." (source: Boston Scientific Corporation)
October
12, 2004 US
Medicare to reimburse for carotid stent use
Guidant's carotid stent device was approved last month, the only such
device on the U.S. market right now. Johnson & Johnson / Cordis is
awaiting approval and several other manufacturers are in the pipeline.
Recent reports (read our summary of the TCT on "Carotid
Stenting") show that this endovascular approach is now
rivaling surgery. Reimbursement is a big breakthrough for this technology. (source: Reuters)
September 28,
2004 Cut
Off at the Bypass: For Most People, Stents and Drugs
Are Usually Safer, Better
A very interesting article by Marc Siegel, MD, a clinical associate professor
of medicine at New York University Medical School, about the treatments
available for coronary artery disease -- bypass surgery, interventional
therapy (angioplasty and stenting) and medical management with drugs.
Taking off on the subject of Bill Clinton's recent surgery, he states, "But
for the vast majority of patients with heart disease, medications are
preferable to surgery, and if trouble occurs, a stent is now the first
choice." (source: Marc Siegel, MD, Washington Post)
September 27, 2004 Guidant
Announces Plans to Initiate Groundbreaking Vulnerable Plaque
Study (source: Guidant Corporation)
The study will involve 700 patients and has been dubbed PROSPECT (Providing
Regional Observations to Study Predictors of Events in the Coronary Tree).
It will utilize intravascular imaging technology from Volcano Therapeutics,
Inc. to collect data about characteristics of lesions not causing symptoms
at the time of treatment. The company's press release explains, "The
cause of most heart attacks was once believed to be the gradual closing
of arteries over time as plaque build-up slowly increased restricting
blood and oxygen flow to the heart. However, the vast majority of heart
attacks are now believed to be triggered by the rupture of a lipid-rich
vulnerable plaque hidden under the surface of the artery wall, causing
blood to clot on the plaque and suddenly block the artery." These
plaques are not detectable through stress tests or even angiograms, but
through Intravascular
Ultrasound. related stories: Volcano
Therapeutics, Inc. Announces Collaboration in Pioneering Vulnerable
Plaque Study -- Volcano Therapeutics, Inc.
September 16, 2004 Guidant
Receives FDA Approval for Small Vessel Cobalt Chromium
Coronary Stent
The company states that this "highly deliverable new stent broadens
Guidant’s market-leading metallic stent portfolio." (a.k.a. "bare
metal stent" -- Guidant's initial attempts at developing a drug-eluting
stent met with failure and it is now a marketing partner with Johnson & Johnson
/ Cordis for the Cypher stent. However, Guidant will be presenting early
results from its new "Spirit First" drug-eluting stent at the
TCT meeting later this month.) (source: Guidant Corporation)
September
10, 2004 Clinton
spurs epidemic of heart checks
"Hospitals around the country are seeing an epidemic of "Clinton syndrome" as
worried, middle-aged men take the former president's heart problems to heart
and rush to get their own tickers checked. At UMass Memorial Medical Center in
central Massachusetts, five cardiac catheterization rooms stayed open extra hours
to do angiograms -- $5,000 tests that are the gold standard for checking arteries
for blockages." (source: Associated Press / Alex Williams, New York Times)
September 9, 2004 Patients,
others push for angioplasty
Though speakers at Tuesday’s public hearing at New Britain General
Hospital came from different walks of life, all agreed that New Britain
General should be able to offer the most comprehensive emergency heart
care available. (source: Scott Whipple, New Britain [CT] Herald)
September 8, 2004 LI
congressman recently had angioplasty
Bill Clinton wasn't the only Democrat having heart surgery over the Labor
Day weekend in New York. Rep. Tim Bishop (D-Southampton) underwent successful
angioplasty for a blocked artery on Sunday, but already returned to work
in Washington on Tuesday. (source: Newsday)
August 31, 2004 Guidant
Receives First U.S. Approval for New Therapy Designed to
Reduce Risk of Stroke
The company announced that the FDA has approved its carotid stent system,
a combination of the stent and filter (to prevent plaque from breaking
off and travelling to the brain). It is the first such system approved
for the U.S. and offers a minimally invasive alternative to the widely-used
open surgical procedure known as "carotid endarterectomy".
Approval of this system moves the field of medicine one more step away
from surgery and towards endovascular, or catheter-based, therapy. For
an extensive look at the history of vascular (non-cardiac) medicine and
the current controversy surrounding this evolution, view our documentary "Vascular
Pioneers" on our companion site at www.VascularTherapy.Org. (source: Guidant Corporation)
August 25, 2004 Boston
Scientific Announces FDA Clearance for Peripheral Cutting
Balloon™ Microsurgical Dilatation Device
The Peripheral Cutting Balloon device features tiny, longitudinally mounted
atherotomes (microsurgical blades) on the surface of an angioplasty balloon
and will be used to treat patients who are currently undergoing hemodialysis
for End Stage Renal Disease (ESRD). This is the second approval by the
FDA this week for a Boston Scientific interventional device. (source: Boston Scientific Corporation)
August 23,
2004 Boston
Scientific Announces FDA Clearance for FilterWire EZ™ Embolic
Protection System
The FilterWire EZ System is a low-profile embolic filter which captures
embolic material that becomes dislodged during balloon angioplasty and
stenting procedures for the treatment of saphenous vein graft (SVG) disease.
Cardiac surgeons use the saphenous vein as a graft in coronary bypass
surgery -- if and when the graft clogs up, an interventional procedure
is used to open it. The FilterWire EZ is an improvement over Boston Scientific's
earlier device (the EX, approved a little over a year ago) and has been
used in Europe since September 2003. (source: Boston Scientific Corporation)
August 14, 2004 Iraqi
Cleric Grand Ayatollah Ali Sistani Has Angioplasty in London
Iraq's most influential Shia leader, 73-year-old Grand Ayatollah Ali
Sistani, is in a stable condition after undergoing angioplasty at the
world-renowned Harefield heart hospital in London. (source: BBC News)
July 29, 2004 Bowie
back on form in wake of heart op
A month after undergoing emergency heart surgery (actually, "angioplasty",
ed.) David Bowie looked to have completed a remarkable recovery as he
made his first public appearance in New York. (source: Edward Black and Lauren Stewart, The Scotsman)
July 26, 2004 Guidant
Announces U.S. Launch of Next-Generation Coronary Dilatation
Catheter
Guidant today announced the U.S. launch of the newest in the company’s
line of coronary dilatation catheters, the VOYAGER™ rapid-exchange
(RX) Coronary Dilatation Catheter, having received F.D.A. approval. Dilatation
catheter, a.k.a. "balloons", are used in a variety of interventional
procedures, sometimes to "pre-dilate" a blockage before a stent
is placed; sometimes to open up a stent that has reclosed over time.
The system combines several exciting new technologies to enhance overall
performance,” said John Lassetter, M.D., of McKay-Dee Hospital
Center in Ogden, Utah. “The low-profile tapered tip contributes
to overall system deliverability, which is important for successful treatment
of patients with significant coronary artery disease.” (source: Guidant Corporation)
July 17, 2004 Boston
Scientific to Recall Additional Coronary Stent Systems
The company announced today that it is expanding its recall of the Taxus
stent system, as well as some lots of the Express2 bare metal stent.
Problems had occurred in a small number of stents, having to do with
the deflation and subsequent withdrawal of the delivery balloon on which
the stent is mounted. An earlier recall was limited to two manufacturing
lots. Most important for patients is that "...today's action
does not affect patients who have already received these stents, because
the difficulty is with the delivery system and occurs at the time of
insertion, not afterward." (source: Boston Scientific Corporation)
July 8, 2004 David
Bowie Has Emergency Angioplasty
Thinking he had a pinched nerve in his shoulder, rock-legend Davie Bowie
sought treatment last month in Germany, in the midst of his current tour.
Turns out he had a severely blocked coronary artery and was immediately
treated with emergency angioplasty. Hoping to return to touring next
month, Bowie said, "I can't wait to be fully recovered and get back
to work again...I tell you what, though, I won't be writing a song about
this one." Angioplasty.org hopes Mr. Bowie reconsiders -- after
all, when he was recording his great album "Heroes" in England,
Andreas Gruentzig was creating the first angioplasty balloon with Krazy
Glue on the kitchen table of his apartment in Zurich. (source: BBC)
June 23, 2004 Silver
lining: Natick firm marks 25 years selling medical devices
A brief overview of Boston Scientific on its 25th anniversary, celebrated
yesterday by employees and co-founders Pete Nicholas and John Abele. (source: Craig M. Douglas, MetroWest Daily News)
June 22, 2004 Boston
Scientific Announces $1 Million Gift to Doctors Without
Borders
The company, as part of celebrating its 25th anniversary, announced that
it plans to make a $1 million gift to Doctors Without Borders, an international
medical humanitarian organization, because of the its work providing
access to medical care for populations suffering from extreme hardships.
Doctors Without Borders (website)
delivers emergency aid to victims of armed conflict, epidemics, and natural
and man-made disasters, and to others who lack health care due to social
or geographical isolation. (source: Boston Scientific Corporation)
June 9, 2004 Biophan,
Boston Scientific extend collaboration
Rochester, NY-based Biophan has been working on a coating for medical
devices that allows MRI imaging. The implications of being able to image
metallic devices such as stents, etc. could potentially be very important,
for example, in eliminating the costs, discomfort and potential complications
of diagnostic angiography. (source: Steve Lewis, Nanobiotech News)
April 21, 2004 Cordis
Endovascular's Carotid Stent System Recommended for Approval
by FDA Advisory Panel
The company today reported the Circulatory System Devices Panel of the
U.S. Food and Drug Administration (FDA) recommended approval of the company's
new Cordis Carotid System which consists of two components: the PRECISE® Nitinol
Self-Expanding Stent and the ANGIOGUARD™ Emboli Capture Guidewire.
These products currently are approved for use in carotid arteries outside
the U.S. (source: Cordis Corporation)
March
25, 2004 Boston
Scientific and EndoTex Interventional Systems, Inc. Announce
Completion Of Enrollment In Carotid Stenting Trial The clinical trial, known as CABERNET, uses the EndoTex
NexStent™ Carotid Stent in conjunction with the Boston
Scientific FilterWire EZ™ Embolic Protection System
to treat patients who are at high risk for a carotid endarterectomy.
Although the FilterWire EZ is available in Europe, both devices
are limited to investigational use in the United States.
Endovascular approaches such as these to traditionally "open" surgical
procedures are revolutionizing vascular surgery. To get a
more comprehensive view of this revolution, and its background,
you can view online our recent video "Vascular
Pioneers: Evolution of a Specialty", hosted by our
sister site, VascularTherapy.Org. (source: Boston Scientific Corporation)
March 10, 2004 Doctors
see vascular system as road to treatment
An interesting overview article about how the whole field of "endovascular" therapy
has been replacing open surgery in the treatment of so many diseases.
It was Charles
Dotter and subsequent pioneers of angioplasty who first envisioned
the circulatory system of the body as a highway, in which therapy could
be delivered. Certainly this has occurred in the heart, with angioplasty
and stenting now more used than bypass surgery. For a full view of how
the field of vascular surgery has been and is being affected by the switch-over
to endovascular, you can view online our recent video "Vascular
Pioneers: Evolution of a Specialty" -- it's a 52 min
documentary (divided into chapters for easy viewing) and features 20
of the most prominent vascular and endovascular surgeons practicing today,
hosted by our sister site, VascularTherapy.Org. (source: Debra Sherman and Julie Steenhuysen, Reuters)
March 10, 2004 Data
Show Heart Imaging Helps Physicians
Dr. John J. Mahmarian, lead investigator of the INSPIRE clinical trial
which tested the value of stress myocardial perfusion imaging (MPI) said
of the findings, "This is a significant breakthrough because the
current perception is that a heart attack sufferer needs to undergo coronary
angiography, or surgical procedure, to evaluate the damage of the heart.
This study demonstrated that patients found to be at low risk by MPI
also are at low risk of a second heart attack and therefore unlikely
to benefit from coronary angiography." This new non-invasive imaging
technique may ultimately significantly reduce the need for angiograms
and/or angioplasties performed on a specific set of heart attack patients. (source: Baylor College of Medicine)
March 9, 2004 Emory
researchers find race and gender gaps in treatment of heart
attack
Emory Heart Center researchers studied the records of 672,817 white and
black patients younger than 75 years of age. "We found that African-American
women and men have continued to receive less aggressive management than
white men after myocardial infarction," says Emory investigator
Viola Vaccarino MD, Ph.D., lead author of the study. Dr. Vaccarino says
the researchers were surprised to discover there has been no trend toward
a lessening of the treatment gaps for women and blacks in recent years. (source: Emory University Health Sciences Center)
March 8, 2004 Exercise
As Good As Angioplasty For Some Heart Patients
Better results at half the cost, study from the University of Leipzig
finds. It's a program that "makes excellent biological sense" for
patients with narrowed coronary arteries but no major symptoms other
than angina, says Dr. Richard A. Stein, chief of medicine at Beth Israel
Medical Center Singer division in New York and a spokesman for the American
Heart Association. (source: Ed Edelson, HealthDay)
March 8, 2004 Striking
Benefits Found In Ultra-Low Cholesterol(source:
Rob Stein, Washington Post) New
Conclusions on Cholesterol (source: Gina
Kolata, New York Times) Comparison
of Intensive and Moderate Lipid Lowering with Statins after
Acute Coronary Syndromes (source: New England
Journal of Medicine -- in PDF format) Intensive
Statin Therapy — A Sea Change in Cardiovascular Prevention (source:
Eric J. Topol, MD, Editorial in New England Journal of Medicine
-- in PDF format)
Presented at the American College of Cardiology meeting, two new studies
show that reducing LDL ("bad cholesterol") levels even lower
than current recommendations resulted in additional significant reductions
in heart attacks and the need for angioplasty and bypass surgeries. Patients
were given Lipitor, a widely-used statin drug to reduce the LDL. The
findings are being hailed by leading cardiologists in superlatives, such
as "sea change", "breakthrough", and "a turning-point
for the field". The above headlines link to two articles in the
news media, as well as two links to the "early release" from
the New England Journal of Medicine of one of the studies, and an editorial
by Eric J. Topol, MD of the Cleveland Clinic
March 7, 2004 Guidant's
Carotid Artery Stenting Trials Demonstrate Positive Outcomes
in High-Risk Patients as Alternative to Surgery to Reduce
the Risk of Stroke
A company press release announced positive results in the ARCHeR (ACCULINK
for Revascularization of Carotids in High Risk Patients) series of clinical
trials. The ARCHeR trials were designed to evaluate the safety and efficacy
of carotid artery stenting as a minimally invasive alternative for treating
carotid artery disease and reducing the risk of stroke in patients either
ineligible or at high risk for surgery. “ Results from the ARCHeR trials
point to the potential of carotid artery stenting as an effective therapy
for the thousands of patients with carotid artery disease who, because
of their risk and co-morbidity factors, are not well-treated by standard
carotid surgery,” said William Gray, M.D., director of Endovascular Care
at the Swedish Medical Center in Seattle, Washington. “Carotid stenting
appears poised to become a realistic treatment option for these high-risk
patients.” (source: Guidant Corporation)
February 27, 2004 FDA
Posts New Web Site on Heart Disease
The Food and Drug Administration today posted a new web site on cardiovascular
disease, Heart Health Online (www.fda.gov/hearthealth).
The web site focuses on FDA-regulated products to prevent, diagnose,
and treat cardiovascular disease. It describes cardiovascular conditions,
and it links to detailed information about specific diagnostic tests,
medications, medical devices, and healthy lifestyles. The web site will
be expanded monthly with new conditions and treatments. (source: United States Food and Drug Administration)
February 20, 2004 Boston
Scientific Announces Settlement of All Litigation with
Guidant
According to the company, "All pending disputes between the companies
will be immediately dismissed. In addition, the companies have agreed
to cross license patents in certain specified technology areas." (source: Boston Scientific Corporation)
February 19, 2004 Boston
Scientific Receives Canadian License for its Carotid Wallstent® System
Company announces Canadian approval of its stent that is used in keeping
open carotid arteries -- a procedure that is more and more being used
as a less-invasive alternative to open surgery. (source: Boston Scientific Corporation)
February 18, 2004 Enrollment
Complete in First Randomized Head-to-Head Trial Of Drug-eluting
Coronary Stents
Cordis announced that enrollment of patients in its clinical trial matching
its own Cypher drug-eluting stent with Boston Scientific's Taxus is complete
and that results of this comparison should be available by the end of
the year. (source: Cordis Corporation)
February 17, 2004 Medical
devices have been a bright spot
A health article -- this time, economic health -- an interesting article
about how the Minnesota economy has been helped by the concentration
of four of the largest medical device companies: Boston Scientific (see
press release below), Guidant, Medtronic and St. Jude. (source: Janet Moore, Star Tribune)
February 17, 2004 Boston
Scientific Announces Expansion Plans in Minnesota
"We've been growing steadily, and we've outgrown our existing space," said
Paul LaViolette, Boston Scientific Senior Vice President and Group President,
Cardiovascular. "Our expansion plans for Minnesota reflect our expectation
of continued growth, driven by our anticipated U.S. launch of TAXUS this quarter
as well as other products in the pipeline." (source: Boston Scientific Corporation)
February 9, 2004 Depression
and Cardiovascular Sequelae in Postmenopausal Women
A large proportion of older women report levels of depressive symptoms
that are significantly related to increased risk of CVD death and all-cause
mortality, even after controlling for established CVD risk factors. Whether
early recognition and treatment of subclinical depression will lower
CVD risk remains to be determined in clinical trials. (source: Archives of Internal Medicine)
February 9, 2004 Company Ties Gene to Risk of
Heart Attack and Stroke
An Icelandic company states it has discovered a "variant gene that
doubles the risk of heart attack and stroke among Icelanders who carry
it". The announcement is not without controversy, but the article
quotes Dr. Eric Topol of the Cleveland Clinic, co-author of the paper,
called the finding "a signal of a really big step forward." (source: Nicholas Wade, New York Times -- Times requires registration;
it is free)
February 5, 2004 Angioplasty
an Option for Clogged Brain Arteries
Not heart-related, but this report from the American Stroke Association's
annual meeting in San Diego discusses the fact that angioplasty clears
clogged brain arteries and prevents stroke in people who fail to respond
to medication. (source: Robert Preidt, HealthDay)
February 4, 2004 Even
Very Elderly Patients Can Benefit From Angioplasty or Bypass
A study from Haifa, Israel indicates that selected patients 80 or older
can do as well as those a decade younger. Christopher P. Cannon, MD,
FACC with Brigham and Women’s Hospital in Boston, Massachusetts
comments, "“In general there has been reluctance to treat
the elderly, especially octogenarians, as aggressively as younger patients...this
study suggests we need to be more aggressive with our elderly patients." You
can read the entire study in PDF format here. (source: Journal of the American College of Cardiology)
February 4, 2004 New
guidelines take a personal approach to preventing cardiovascular
disease in women
New guidelines, based on a woman’s individual cardiovascular health,
were released today by the AHA. According to Lori Mosca, M.D., M.P.H.,
Ph.D., chair of the writing group and director of preventive cardiology
at New York-Presbyterian Hospital/Columbia University Medical Center, “The
concept of cardiovascular disease (CVD) as a ‘have-or-have-not’ condition
has been replaced with the idea that CVD develops over time and every
woman is somewhere on the continuum.” Access
a PDF file of the guidelines here. (source: American Heart Association)
February 1, 2004 Technology
improves patient outcomes
Angioplasty.Org is always interested in the impact of medical technology
at the local level. This is a piece from Evansville, Indiana about how
the practice of cardiology, as well as other specialties, has changed
as a result of these breakthroughs. (source: Ella Johnson, Evanville Courier & Press)
January 29, 2004 Angioplasty
for Heart Attack Particularly Helpful for Women
The Reuters article states, "People suffering a heart attack may
be treated with clot-busting drugs or taken directly to the OR to have
the blockage in their coronary arteries cleared by angioplasty. The latter
strategy, it seems, helps women more than men." The complete study
can be read in the American
Heart Journal (free registration required). (source: Reuters Health, American Heart Journal)
January 21, 2004 Arterial
Puncture Closing Devices Compared With Standard Manual
Compression After Cardiac Catheterization
Researchers in Vienna, Austria conducted a "meta-study" of
30 other studies "to assess the safety and efficacy of APCDs (Angioseal,
Vasoseal, Duett, Perclose, Techstar, Prostar) compared with standard
manual compression in patients undergoing coronary angiography or percutaneous
vascular interventions." While indicating that poor methodology
in some of the studies may have affected the results, the researchers
concluded that "...there is only marginal evidence that APCDs are
effective and there is reason for concern that these devices may increase
the risk of hematoma and pseudoaneurysm." The topic of femoral closure
devices, which significantly reduce the amount of time patients need
to lay still and be immobilized post-angioplasty, is one of the more
popular threads in our FORUM. Angioplasty.org invites comments on this
article and experiences of patients and healthcare professionals in our FORUM
topic. (source: Journal of the American Medical Association)
January 19, 2004 Modified
Gene Therapy Better for Heart
Researchers in Scotland are working to target the delivery of gene therapy
in what the author calls "budding field of gene therapy for heart
disease". (source: Ed Edelson, HealthDay)
January 18, 2004 Heart
attack roulette?
Another article about a community's struggle with providing the best
treatment for heart attack victims -- angioplasty. (source: Henry L. Davis, Buffalo News)
January 16, 2004 Boston
Scientific Completes Enrollment Of Carotid Stenting Clinical
Trial
In the latest example of how interventional catheter-based medicine has
spread into many specialties, the Company announced that enrollment is
completed in the BEACH clinical trial which is using the Company's FilterWire
EZ™Embolic Protection System and Carotid Wallstent® Monorail® Endoprosthesis
to treat patients who are at high risk for the surgical treatment of
carotid endarterectomy. In the procedure, a stent (larger than the type
used in coronary angioplasty) is placed in the carotid (neck) artery. (source: Boston Scientific Corporation)
January 16, 2004 Declining
Prevalence of No Known Major Risk Factors for Heart Disease
and Stroke Among Adults --- United States, 1991--2001
Despite publicity and widespread knowledge about the need for lowering
the risk factors associated with heart disease (high blood pressure,
high cholesterol, diabetes, smoking, and obesity) the number of Americans
with one or more of these factors increased in the past decade -- a relative
increase of almost 10%, while the relative percentage of people with
no risk factors at all went down by almost 14%. The CDC says, "These
findings underscore the potential for an increased burden of heart disease
and stroke on the health-care system. To prevent the debilitating outcomes
of heart disease and stroke among the aging U.S. population, increased
prevention efforts and treatment interventions are needed. (source: Morbidity and Mortality Weekly Report from the Centers
for Disease Control)
January 15, 2004 'Opportunities
great,' according to interventional cardiologist
Speaking at the JPMorgan Healthcare Conference in San Francisco, Martin
Leon, MD provided an status overview of the current field of interventional
cardiology, said, "It's a great time to be an interventionalist," he
said. "the opportunity to provide solutions to important medical
problems is great." The article provides a good picture of where
cardiology is going. (Read
our interview with Dr. Leon in the Angioplasty.Org library). (source: Jim Stommen, BioWorld Today)
January 14, 2004 New
evidence bolsters use of heart scans
Now there is evidence that CT scans for calcium can play a significant
role in predicting cardiac deaths and making treatment decisions for
the millions of people in the middle-range of coronary risk. (source: Thomas M. Burton, The Wall Street Journal)
January 7, 2004 Strict
Blood Sugar Control Key for Diabetic Heart Patients
A report on a study in today's Journal of the American College of Cardiology
that finds controlling blood sugar levels in diabetic heart patients
after angioplasty and stenting may be very important in reducing restenosis. (source: Karen Pallarito, HealthDay)
January 7, 2004 FDA
Clears Xtrak Support Catheter For Crossing Difficult Lesions
Company press release describes their TOPS™ support catheter that
the FDA has now approved for sale in the U.S. It can be used over standard
guide wires and can assist in getting an angioplasty balloon through
narrow or total occlusions in the artery. (source: Xtrak Medical, Inc.)
January 1, 2004 New
stats show heart disease still America's No. 1 killer,
stroke No. 3
Statistics compiled from 2001 show that coronary heart disease alone
is the single largest killer of Americans. The disease continues to devastate
women as it accounts for one in five women’s deaths. The statistics
also show that 2/3 of the U.S. adult population is overweight or obese,
and that 1/3 of all deaths from smoking-related illness (almost 1/2 million
annually) are cardiovascular-related. (source: American Heart Association)
January 1, 2004 Heart
disease goes beyond the heart
In a companion article to the one above, the American Heart Association
discusses what the current statistics shows about diseases related to
cardiovascular disease (sometimes the same disease process, but in a
different part of the body). These include: congestive heart failure,
peripheral arterial disease (clogged vessels in the arms and legs), end-stage
renal disease and venous thromboembolism (blood clot). (source: American Heart Association)